{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:53:29Z","timestamp":1793141609892,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.kint.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T23:21:19Z","timestamp":1753744879000},"page":"780-790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management recommendations for kidney transplantation in patients with plasma cell dyscrasia"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8168-5811","authenticated-orcid":false,"given":"Naoka","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Blosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-6400","authenticated-orcid":false,"given":"Allison B.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samhita","family":"Boppana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samip","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raviprasenna","family":"Parasuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Campagnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-238X","authenticated-orcid":false,"given":"Anuja","family":"Java","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Bhasin-Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala","family":"Khirfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9072-9871","authenticated-orcid":false,"given":"Mariam P.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos Z.","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Kumar","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-0241","authenticated-orcid":false,"given":"Sabine","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.07.011_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2025.07.011_bib3","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.kint.2025.07.011_bib5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2025.07.011_bib6","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/ndt\/gfac196","article-title":"Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA","volume":"37","author":"Ng","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.07.011_bib7","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ekir.2022.01.003","article-title":"Kidney transplant outcomes of patients with multiple myeloma","volume":"7","author":"Heybeli","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.07.011_bib8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1097\/TP.0000000000002449","article-title":"Kidney transplant in the era of modern therapy for multiple myeloma","volume":"102","author":"Huskey","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.07.011_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14541","article-title":"Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: a case series","volume":"36","author":"Dinh","year":"2022","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.07.011_bib10","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2025.07.011_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2025.07.011_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.07.011_bib13","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.kint.2025.07.011_bib14","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2013.166","article-title":"A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control","volume":"27","author":"Paiva","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2025.07.011_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","article-title":"Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma","volume":"69","author":"Lum","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.07.011_bib17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.transproceed.2018.01.014","article-title":"Severe renal allograft rejection resulting from lenalidomide therapy for multiple myeloma: case report","volume":"50","author":"Walavalkar","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.07.011_bib18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.07.011_bib19","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib20","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib21","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13050","article-title":"Increasing therapy-related myeloid neoplasms in multiple myeloma","volume":"49","author":"Fern\u00e1ndez-Caballero","year":"2019","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.kint.2025.07.011_bib23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00007890-198612000-00005","article-title":"Renal transplantation in 45 patients with amyloidosis","volume":"42","author":"Pasternack","year":"1986","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.07.011_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.kint.2020.06.036","article-title":"A study from the Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis","volume":"99","author":"Heybeli","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.07.011_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.07.011_bib27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.16246","article-title":"Kidney transplantation in AL amyloidosis: is it time to maximize access?","volume":"188","author":"Sathick","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2025.07.011_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfaa293","article-title":"Renal transplant outcomes in amyloidosis","volume":"36","author":"Law","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.07.011_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through the International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2025.07.011_bib30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/TP.0000000000005191","article-title":"Kidney transplant outcomes in amyloidosis: US national database study","volume":"109","author":"Yamauchi","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.07.011_bib31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/TP.0000000000001930","article-title":"Patient and kidney allograft survival in recipients with end-stage renal disease from amyloidosis","volume":"102","author":"Sawinski","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.07.011_bib32","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000004443","article-title":"Kidney transplantation in patients with monoclonal gammopathy of renal significance","volume":"107","author":"Sprangers","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.07.011_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2215\/CJN.05750710","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft","volume":"6","author":"Nasr","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.07.011_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft","volume":"94","author":"Said","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.07.011_bib36","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.ekir.2023.10.013","article-title":"The uncertainty puzzle of monoclonal gammopathy of renal significance without detectable clones","volume":"8","author":"Shah","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.07.011_bib37","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.07.011_bib38","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/TP.0000000000002577","article-title":"Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies","volume":"103","author":"Buxeda","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.07.011_bib39","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.07.011_bib40","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.07.011_bib41","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2025.07.011_bib42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.07.011_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib45","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLML.2010.n.053","article-title":"Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future","volume":"10","author":"Waxman","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.kint.2025.07.011_bib46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2025.07.011_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2025.07.011_bib48","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000337482","article-title":"Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation","volume":"35","author":"Naina","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2025.07.011_bib50","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.transproceed.2015.08.023","article-title":"Outcomes of monoclonal gammopathy of undetermined significance in patients who underwent kidney transplantation","volume":"47","author":"Bancu","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.07.011_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.transproceed.2014.11.021","article-title":"Follow-up monoclonal gammopathy of undetermined significance in kidney transplant","volume":"47","author":"Cu\u00e9llar-Garc\u00eda","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.07.011_bib52","article-title":"The evolution of monoclonal gammopathy of undetermined significance in kidney transplant recipients","volume":"5","author":"Gagnon","year":"2019","journal-title":"Transplant Direct"},{"key":"10.1016\/j.kint.2025.07.011_bib53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ndt\/gfad144","article-title":"Monoclonal gammopathy of unknown significance in kidney transplanted patients: novel insights into long-term outcomes","volume":"39","author":"Meuleman","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.07.011_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2025.07.011_bib55","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.kint.2025.07.011_bib56","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1111\/tri.1992.5.s1.23","article-title":"Monoclonal immunoglobulins in patients with renal transplants: characterization, evolution and risk factors","volume":"5","author":"Chakalarovski","year":"1992","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.07.011_bib57","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/oxfordjournals.ndt.a027215","article-title":"Monoclonal gammopathy after intense induction immunosuppression in renal transplant patients","volume":"11","author":"Passweg","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.07.011_bib58","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/01.TP.0000129065.31427.96","article-title":"Infection with human herpesvirus 8 and transplant-associated gammopathy","volume":"77","author":"Regamey","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.07.011_bib59","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.transproceed.2004.09.046","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr virus (EBV) latently infected B lymphocytes in long-term renal transplant patients","volume":"36","author":"Babel","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.07.011_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.kint.2025.07.011_bib61","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.kint.2025.07.011_bib62","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2025.07.011_bib63","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.07.011_bib64","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib66","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.07.011_bib67","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib68","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib69","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2025.07.011_bib70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib71","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.07.011_bib72","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.07.011_bib73","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/ndt\/gfaf004","article-title":"Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR T-cells","volume":"40","author":"Charkviani","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.07.011_bib74","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.27063","article-title":"Teclistamab in patients with multiple myeloma and impaired renal function","volume":"98","author":"Joiner","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825005769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825005769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:19:39Z","timestamp":1760825979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825005769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0085253825005769"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.07.011","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management recommendations for kidney transplantation in patients with plasma cell dyscrasia","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}